1. Market Research
  2. > Biotechnology Market Trends
  3. > Biotechnology Analysis & Statistics in Japan, June 2019

Biotechnology Analysis & Statistics in Japan, June 2019

Customer Support

Talk to Veronica

+1 718 514 2762

Publishers

  • All
    • MP Advisors

All regions

data types

1-5 of 5 reports

Japan Biosimilars – A start of Authorized Biosimilar Era? - Biosimilar/BioPharma CMO opportunities – JP Conglomerates – A definite role to play for Global Market!

Japan Biosimilars – A start of Authorized Biosimilar Era? - Biosimilar/BioPharma CMO opportunities – JP Conglomerates – A definite role to play for Global Market!

  • $ 4000
  • Industry report
  • August 2017

Major JP Innovator vs. Early entrant Mid size Japanese companies- TA focus approach – A Win Win Game!In this report, we attempt to evaluate key upcoming opportunity for Japan BS market, its competitive ...

  • Industries : Medical Biotechnology
  • Countries : Japan
JP Giants leaning in for becoming a Speciality Global PharmaSakigake designation

JP Giants leaning in for becoming a Speciality Global PharmaSakigake designation

  • $ 2500
  • Industry report
  • March 2016

In this report- we analyzed therapy focus, changing Strategies, pipeline and key growth drivers of 12 major Japanese biopharma companies (Pure play innovators/ Innovators+ Generics/Pure play generics) ...

  • Industries : Medical Biotechnology
  • Countries : Japan, World, United States
Japan Biosimilar- Active Players In Quest of a Specialty & Niche BS space

Japan Biosimilar- Active Players In Quest of a Specialty & Niche BS space

  • $ 4000
  • Industry report
  • January 2016

Filgrastim BS and Lantus BS Approval- Encouraging uptake and a lesson to fast track JP approval based on Ex-Japan data! Remicade biosimilar “NK” – A slow start does not pull back NK in starting PhIII ...

  • Industries : Medical Biotechnology, Biopharmaceutical, Biopharmaceutical
  • Countries : Japan
New Phase of Mab biosimilar knocks the door  Biosimilar Oppurtunities In Japan

New Phase of Mab biosimilar knocks the door Biosimilar Oppurtunities In Japan

  • $ 4000
  • Industry report
  • February 2015

The launch of Remicade biosimilar in Dec-2014 in the Japan pharma market demonstrated its changing regulatory environment; it is faster than U.S. in adapting to biosimilar use. After nine years of continuous ...

  • Industries : Medical Biotechnology, Biopharmaceutical, Biopharmaceutical
  • Countries : Japan
Japan Pharma  Outlook 2015: 2015 –Year to Watch out for Authorized Generics (AGs), Biosimilars and Overseas Strategic Initiatives

Japan Pharma Outlook 2015: 2015 –Year to Watch out for Authorized Generics (AGs), Biosimilars and Overseas Strategic Initiatives

  • $ 2000
  • Industry report
  • January 2015

The new pricing system adopted in Japan from April -2014 (Annexure 1) is a game changer initiative. It pains most of the companies - whether generic or innovator. The most of the companies are revalidating ...

  • Industries : Medical Biotechnology
  • Countries : Japan



ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.

Make sure you don’t miss any news and follow us on